Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese


Forum Home Forum Home > General Discussion > General Discussion
  New Posts New Posts RSS Feed - New Approach To TB - Take its invisibility away
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Online Discussion: Tracking new emerging diseases and the next pandemic

New Approach To TB - Take its invisibility away

 Post Reply Post Reply
Author
Message
Technophobe View Drop Down
Senior Moderator
Senior Moderator
Avatar

Joined: January 16 2014
Location: Scotland
Status: Offline
Points: 51730
Post Options Post Options   Thanks (0) Thanks(0)   Quote Technophobe Quote  Post ReplyReply Direct Link To This Post Topic: New Approach To TB - Take its invisibility away
    Posted: September 12 2018 at 5:35am
[Technophobe: TB is called "The Great Pretender" by many doctors and scientists. This is both because it mimics other diseases and because it hides within the body. It does the latter by by turning off the imune response of its host. This reduces the symptoms and allows the disease to spread unhinderred until it becomes fatal. This promising new approach takes away its 'cloak of invisibility' allowing the immune system to spot it and then attack.][i/]

11 September 2018

Scientists develop new drug treatment for TB

Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.

The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.

The drug- which works by targeting Mycobacterium tuberculosis’ defences rather than the bacteria itself - can also take out its increasingly commonly antibiotic resistant strains.

The research funded by the Medical Research Council – is published today in the Journal of Medicinal Chemistry.

Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease.

About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated in 2018, up from the 6.3 million in 2016.

It is most common in Africa, India and China, but on the rise in the UK with London often described as the TB capital of Europe.

Patients are forced to take a cocktail of strong antibiotics over 6 to 8 months, often enduring unpleasant side effects with a 20% risk that the disease will return.

But now The University of Manchester team’s discovery has been proven effective in guinea pigs at Rutgers University in the United States.

The animals with acute and chronic TB infection were treated with the compound, which was discovered after investigating dozens of other derivatives and compounds thought to have similar properties.

Professor Lydia Tabernero is the project leader. She said: "The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable.

“For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients.

And with current treatments, there’s no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high.

But by disabling this clandestine bacteria’s defences we’re thrilled to find a way that enhances the chances of the body’s immune system to do its job, and thus eliminate the pathogen.”


“The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable"

Professor Lydia Tabernero„

Mycobacterium Tuberculosis secretes molecules called Virulence Factors - the cell’s secret weapon -which block out the immune response to the infection, making it difficult to treat.

The team identified one Virulence Factor called MptpB as a suitable target, which when blocked allows white blood cells to kill Mycobacterium Tuberculosis in a more efficient way

Professor Tabernero added: “The great thing about MptpB is that there’s nothing similar in humans - so our compound which blocks it is not toxic to the human cells.

“Because the bacteria hasn’t been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant.

TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough.

The next stage of our research is to optimise further the chemical compound, but we hope Clinical trials are up to four years away.”

Structure-based design of MptpB inhibitors that reduce multi-drug-resistant Mycobacterium tuberculosis survival and infection burden in vivo is published in the Journal of Medicinal Chemistry

Source and links to more information:   https://www.manchester.ac.uk/discover/news/scientists-develop-new-drug-treatment-for-tb/

[Techno: There is no reason this cannot be combined with antibiotics for a more potent and mix with reduced overall side-effects.]
Absence of proof is not proof of absence.
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down